Current National Comprehensive Cancer Network (NCCN) guidelines offer 6 blood-based and urine-based biomarker tests, each including 3 or fewer markers of PCa (ie, cancer of any grade).5 While consistently outperforming PSA alone,13 these assays have not evolved to reflect current understanding of PCa biology. Here, KLK3 is linked to posterior cortical atrophy.